Oncotarget

Reviews:

The associations between the MAPT polymorphisms and Alzheimer’s disease risk: a meta-analysis

Futao Zhou _ and Danli Wang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43506-43520. https://doi.org/10.18632/oncotarget.16490

Metrics: PDF 919 views  |   HTML 787 views  |   ?  


Abstract

Futao Zhou1 and Danli Wang1

1 College of Medicine & Health, Lishui University, Lishui Zhejiang, China

Correspondence to:

Futao Zhou, email:

Keywords: Alzheimer’s disease, microtubule-associated protein tau, single nucleotide polymorphisms, meta-analysis

Received: November 01, 2016 Accepted: March 15, 2017 Published: March 22, 2017

Abstract

Published studies revealed that the microtubule-associated protein tau (MAPT) gene polymorphisms increased Alzheimer’s disease (AD) risk; the associations of 4 single nucleotide polymorphisms (SNPs, rs242557G/A, rs2471738C/T, rs3785883G/A and rs1467967A/G) of the MAPT gene with AD risk, however, remain inconclusive. Here, we conducted a meta-analysis to investigate the relationship between the MAPT SNPs and AD risk. A significant association of SNP rs242557 with AD risk was found in a dominant [odds ratio (OR) = 1.05, 95% confidence interval (CI) = 1.01, 1.10, P = 0.025] genetic model, and a suggestive association in an allelic (OR = 1.03, 95% CI = 1.00, 1.06, P = 0.078). When APOE epsilon 4 carrier status was included in stratified analysis, this association was even stronger (allelic model for the APOE epsilon 4 positive individuals: OR = 1.24, 95% CI = 1.08, 1.43, P = 0.003). Furthermore, a significant association of SNP rs2471738 with AD risk was found under all the four models (allelic: OR = 1.11, 95% CI = 1.01, 1.20, P = 0.021; dominant: OR = 1.10, 95% CI = 1.00, 1.21, P = 0.046; recessive: OR = 1.18, 95% CI = 1.05, 1.32, P = 0.004; additive: OR = 1.20, 95% CI = 1.07, 1.34, P = 0.002) models. However, pooled results suggest that the neither rs3785883 nor rs1467967 is associated with AD risk under all the four genetic models. In summary, our study provides further evidence of the associations of the MAPT SNPs with AD risk.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16490